Tislelizumab-induced hyperamylasemia: Case report and safety analysis using the FAERS database
Int. Journal of Clinical Pharmacology and Therapeutics · 01.11.2026 · 64 (11) · 623-631
DOI: 10.5414/cp204996 ↗Kurz gefasst
Fallbericht in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.11.2026. Verfasst von Wusimanjiang Aimaiti und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Hyperamylasemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Aimaiti, W., Yu, S., Huang, Y., Yang, L., Wang, S., & Gu, S. (2026). Tislelizumab-induced hyperamylasemia: Case report and safety analysis using the FAERS database. Int. Journal of Clinical Pharmacology and Therapeutics, 64(11), 623-631. https://doi.org/10.5414/cp204996
Vancouver
Aimaiti W, Yu S, Huang Y, Yang L, Wang S, Gu S. Tislelizumab-induced hyperamylasemia: Case report and safety analysis using the FAERS database. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(11):623-631. doi:10.5414/cp204996
BibTeX
@article{Aimaiti2026,
author = {Aimaiti, Wusimanjiang and Yu, Shidan and Huang, Yulong and Yang, Lijuan and Wang, Shuowen and Gu, Shengying},
title = {Tislelizumab-induced hyperamylasemia: Case report and safety analysis using the FAERS database},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
volume = {64},
number = {11},
pages = {623--631},
doi = {10.5414/cp204996}
}
EUVIMED